Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Karmiel
21000
Tel: 972-4-988-9488
Fax: 972-4-988-9489
Website: http://www.protalix.com/
Email: info@protalix.com
292 articles about Protalix Biotherapeutics, Inc.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
11/14/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced the resubmission on November 9, 2022 of a Biologics License Application to the U.S. Food and Drug Administration for PRX–102 for the treatment of adult patients with Fabry disease.
-
Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022
11/7/2022
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022.
-
Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference
9/12/2022
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present in person on Wednesday, September 14, 2022 at 11:00 a.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Protalix BioTherapeutics, Inc. announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference.
-
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results
8/15/2022
Protalix BioTherapeutics, Inc. reported financial results for the second quarter ended June 30, 2022 and provided a business update on recent corporate and regulatory developments.
-
Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022
8/8/2022
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the second quarter 2022 and provide a business update on Monday, August 15, 2022.
-
Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors
6/30/2022
Protalix BioTherapeutics, Inc., announced that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors.
-
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease
5/26/2022
Protalix BioTherapeutics, Inc. announced that five poster presentations are scheduled to be available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities.
-
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
5/16/2022
Protalix BioTherapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a business update on recent corporate and clinical developments.
-
Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022
5/9/2022
Protalix BioTherapeutics, Inc. announced that it will release its financial results for the first quarter 2022 and provide a business update on Monday, May 16, 2022.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
4/4/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced topline results from the BALANCE pivotal Phase III clinical trial evaluating pegunigalsidase alfa, 1 mg/kg, administered every two weeks, compared to agalsidase beta for the treatment of Fabry disease.
-
Fabry disease treatment is going to get new updates as Protalix and Chiesi are seeking approval. This can be a game-changer in the market. Here's more about it.
-
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
3/31/2022
Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2021 and provided a business update on recent corporate and clinical developments.
-
Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022
3/24/2022
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for fiscal year 2021 and provide a business update on Thursday, March 31, 2022.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
3/18/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa for the potential treatment of Fabry disease.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
2/24/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases today announced the submission of a Marketing Authorization Application (MAA) via centralized procedure to the European Medicines Agency (EMA) for pegunigalsidase alfa (PRX–102),
-
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022
2/3/2022
Protalix BioTherapeutics, Inc. announced that there will be two poster presentations regarding the Company's pegunigalsidase alfa or PRX–102 candidate under development for the treatment of Fabry disease at the 18th Annual WORLDSymposium™ 2022, taking place February 7-11, 2022 at the Manchester Grand Hyatt in San Diego, California.
-
Protalix BioTherapeutics Issues 2021 Letter to Stockholders
12/22/2021
Protalix BioTherapeutics, Inc. today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.
-
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
11/15/2021
Protalix BioTherapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.